-
Shareholders' Meeting Information
(Proxy Documents)PROXY 2024 - Genomma Lab Informs The Corporate Bond (Cebures) Program Proposal
pdfPROXY 2024 - Genomma Lab Informs The Dividend Proposal
pdfPROXY 2024 - Genomma Lab Informs The Amount To Be Proposed To The Shareholder’s Meeting For The Cancellation Of Buyback Shares
pdfPROXY 2024 - Genomma Lab informs the amount to be proposed to the Shareholder’s Meeting for the 2024 Share Buyback Program
pdfPROXY 2024 - Genomma Lab informs the amount to be proposed of remuneration for the Board of Directors and The Audit & Corporate Practices Committee Members
pdfPROXY 2024 - Genomma Lab nominees for Board of Directors and Committees to serve from April 2024 to April 2025
pdfPROXY 2023 - Genomma Lab nominees for Board of Directors and Committees to serve from April 2023 to April 2024
pdfPROXY 2023 - Genomma Lab informs the amount to be proposed of remuneration for the Board of Directors and The Audit & Corporate Practices Committee Members
pdfPROXY 2023 - Genomma Lab informs the amount to be proposed to the Shareholder’s Meeting for the 2023 Share Buyback Program
pdfPROXY 2023 - Genomma Lab Informs The Amount To Be Proposed To The Shareholder’s Meeting For The Cancellation Of Buyback Shares
pdfPROXY 2022 - Genomma Lab nominees for Board of Directors and Committees to serve from April 2022 to April 2023
pdfPROXY 2022 - Genomma Lab informs the amount to be proposed of remuneration for the Board of Directors and The Audit & Corporate Practices Committee Members
pdfPROXY 2022 - Genomma Lab informs the amount to be proposed to the Shareholder’s Meeting for the 2022 Share Buyback Program
pdfPROXY 2022 - Genomma Lab informs the proposal to issue a dividend to the shareholders of the Company for an amount of up to 800 million pesos
pdfPROXY 2022 - Genomma Lab informs the proposed amendment to article third of the corporate statutes
pdfPROXY 2021 - Genomma Lab nominees for Board of Directors and Committees to serve from April 2021 to April 2022
pdfPROXY 2021 - Genomma Lab informs the amount to be proposed of remuneration for the Board of Directors and The Audit & Corporate Practices Committee Members
pdfPROXY 2021 - Genomma Lab informs the amount to be proposed to the Shareholder’s Meeting for the 2021 Share Buyback Program
pdf2020 Annual General Meeting Agreements (Spanish Only)
pdfPROXY 2020 - Genomma Lab informs the amount to be proposed of remuneration for the Board of Directors and The Audit & Corporate Practices Committee Members
pdfPROXY 2020 - Genomma Lab nominees for Board of Directors and Committees to serve from April 2020 to April 2021
pdfPROXY 2020 - Genomma Lab informs the amount to be proposed to the Shareholder’s Meeting for the 2020 Share Buyback Program
pdfProxy 2019 - Terms & Amount for Extension of Revolving Debt Securities Program
pdfProxy 2019 - Proposed Amount of Remuneration for Board & Committee Members
pdfProxy 2019 - Proposed Amount for Share Buy Back Program at AGSM 2019
pdfProxy 2019 - Proposed Special Delegates to Formalize Resolutions at the AGSM 2019
pdf
Genomma Lab is committed to enriching the well-being of our society by improving life quality of the consumers of our products via the investigation and analysis of the optimal ingredients for the development and commercialization of our personal care and OTC pharmaceutical products, and in so doing, generating the maximum levels of profitability possible for our investors.
Rodrigo Herrera Aspra
Founder and Chairman of the Board
Corporate Governance
Board Of Directors
-
Chairman
-
Active Vice Chairman of the Board of Directors
-
Independent Board Member
-
Independent Board Member
-
Patrimonial Independent Board Member
-
Independent Board Member
-
Independent Board Member
-
Independent Board Member
-
Propietary Board Member
-
Independent Board Member
-
Independent Board Member
-
Independent Board Member
Auditing and Corporate Practices Committee
-
President
-
Independent Board Member
-
Independent Board Member
